Description Fc Engineered Anti-Human IL-23 p19 Antibody, CDC-Enhanced (BioBet-C046ZP) is a recombinant monoclonal Whole Human antibody against IL-23 p19. This product is a CDC enhanced antibody produced by our proprietary platform.
Indication Plaque psoriasis
Classification Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name IL-23 p19
Full Name IL-23 p19
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype Human IgG1
Indication
Severe Plaque psoriasis
Moderate Plaque psoriasis
Severe Plaque psoriasis
Moderate Plaque psoriasis
Related Products
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.